Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sanofi, Maxygen Ink Dengue Virus Vaccine Agreement

This article was originally published in The Pink Sheet Daily

Executive Summary

$24.5 million-plus licensing deal complements Sanofi’s vaccine work with Maxygen’s technology and could lead to next-generation dengue vaccine, Sanofi tells “The Pink Sheet” DAILY.

You may also be interested in...



Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007

Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.

Maxygen’s Neutropenia Candidate Shows Positive Results In Phase IIa Trial

Firm speculates drug could grab 20 percent to 50 percent of Neulasta’s market share.

Maxygen’s Neutropenia Candidate Shows Positive Results In Phase IIa Trial

Firm speculates drug could grab 20 percent to 50 percent of Neulasta’s market share.

Topics

UsernamePublicRestriction

Register

LL1135866

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel